RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

PURPOSE: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with lower benefit reported in patients with ex21L858R versus ex19del mutations. We investigated if EGFR-activating mutation subt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Kazuhiko, Nadal, Ernest, Garon, Edward B., Nishio, Makoto, Seto, Takashi, Yamamoto, Nobuyuki, Park, Keunchil, Shih, Jin-Yuan, Paz-Ares, Luis, Frimodt-Moller, Bente, Zimmermann, Annamaria H., Wijayawardana, Sameera, Visseren-Grul, Carla, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662911/
https://www.ncbi.nlm.nih.gov/pubmed/34301751
http://dx.doi.org/10.1158/1078-0432.CCR-21-0273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662911/
https://www.ncbi.nlm.nih.gov/pubmed/34301751
http://dx.doi.org/10.1158/1078-0432.CCR-21-0273

Ejemplares similares